A Phase III clinical trial comparing hematopoietic stem cell transplants to immunomodulators is underway.
Multiple sclerosis (MS) is an autoimmune disease characterized by the destruction of the myelin sheath of nerve fibers. There is no cure for the condition, but there are a number of FDA-approved immunomodulators or disease-modifying therapies to reduce relapses and slow disease progression. Despite the availability of these drugs, their varying efficacy, adverse effects, and expense are significant concerns. Therefore, a means to safely and effectively control MS symptoms and progression is still under investigation.